SETTING: Alcohol use increases the risk of multidrug-resistant tuberculosis (MDR-TB) and poses challenges for successful MDR-TB treatment, including the potential for additional adverse events. AIM: To investigate the association between alcohol consumption during MDR-TB treatment and adverse events and treatment outcomes in a cohort of patients in Tomsk, Russia. DESIGN: From 2000 to 2004, retrospective data were collected on 407 MDR-TB patients in Tomsk. Factors associated with treatment outcomes were assessed using logistic regression. RESULTS: Of the 407 patients, 253 (62.2%) consumed alcohol during treatment ('drinkers'), and 367 (90.2%) had at least one documented adverse advent. No significant differences were noted in frequency of adverse events in drinkers vs. non-drinkers. Drinkers had less favourable treatment outcomes (OR 0.28, 95%CI 0.18-0.45). Among drinkers, favourable treatment outcome was associated with adherence to at least 80% of prescribed doses (OR 2.89, 95%CI 1.30-6.43) and the occurrence of an adverse event requiring treatment interruption (OR 2.49, 95%CI 1.11-5.59). CONCLUSIONS: Alcohol use did not appear to increase the risk of adverse events during MDR-TB treatment; however, alcohol consumption was associated with poor outcome. Our findings suggest that individuals who drink alcohol should receive aggressive attention to optimise treatment adherence and manage adverse events.
SETTING:Alcohol use increases the risk of multidrug-resistant tuberculosis (MDR-TB) and poses challenges for successful MDR-TB treatment, including the potential for additional adverse events. AIM: To investigate the association between alcohol consumption during MDR-TB treatment and adverse events and treatment outcomes in a cohort of patients in Tomsk, Russia. DESIGN: From 2000 to 2004, retrospective data were collected on 407 MDR-TBpatients in Tomsk. Factors associated with treatment outcomes were assessed using logistic regression. RESULTS: Of the 407 patients, 253 (62.2%) consumed alcohol during treatment ('drinkers'), and 367 (90.2%) had at least one documented adverse advent. No significant differences were noted in frequency of adverse events in drinkers vs. non-drinkers. Drinkers had less favourable treatment outcomes (OR 0.28, 95%CI 0.18-0.45). Among drinkers, favourable treatment outcome was associated with adherence to at least 80% of prescribed doses (OR 2.89, 95%CI 1.30-6.43) and the occurrence of an adverse event requiring treatment interruption (OR 2.49, 95%CI 1.11-5.59). CONCLUSIONS:Alcohol use did not appear to increase the risk of adverse events during MDR-TB treatment; however, alcohol consumption was associated with poor outcome. Our findings suggest that individuals who drink alcohol should receive aggressive attention to optimise treatment adherence and manage adverse events.
Authors: S S Shin; A D Pasechnikov; I Y Gelmanova; G G Peremitin; A K Strelis; S Mishustin; A Barnashov; Y Karpeichik; Y G Andreev; V T Golubchikova; T P Tonkel; G V Yanova; M Nikiforov; A Yedilbayev; J S Mukherjee; J J Furin; D J Barry; P E Farmer; M L Rich; S Keshavjee Journal: Int J Tuberc Lung Dis Date: 2006-04 Impact factor: 2.373
Authors: S S Shin; A D Pasechnikov; I Y Gelmanova; G G Peremitin; A K Strelis; S Mishustin; A Barnashov; Y Karpeichik; Y G Andreev; V T Golubchikova; T P Tonkel; G V Yanova; A Yedilbayev; M L Rich; J S Mukherjee; J J Furin; S Atwood; P E Farmer; S Keshavjee Journal: Int J Tuberc Lung Dis Date: 2007-12 Impact factor: 2.373
Authors: Jürgen Rehm; Andriy V Samokhvalov; Manuela G Neuman; Robin Room; Charles Parry; Knut Lönnroth; Jayadeep Patra; Vladimir Poznyak; Svetlana Popova Journal: BMC Public Health Date: 2009-12-05 Impact factor: 3.295
Authors: I Y Gelmanova; S Keshavjee; V T Golubchikova; V I Berezina; A K Strelis; G V Yanova; S Atwood; M Murray Journal: Bull World Health Organ Date: 2007-09 Impact factor: 9.408
Authors: E J Ragan; M B Kleinman; B Sweigart; N Gnatienko; C D Parry; C R Horsburgh; M P LaValley; B Myers; K R Jacobson Journal: Int J Tuberc Lung Dis Date: 2020-01-01 Impact factor: 2.373
Authors: Zhiyi Lan; Nafees Ahmad; Parvaneh Baghaei; Linda Barkane; Andrea Benedetti; Sarah K Brode; James C M Brust; Jonathon R Campbell; Vicky Wai Lai Chang; Dennis Falzon; Lorenzo Guglielmetti; Petros Isaakidis; Russell R Kempker; Maia Kipiani; Liga Kuksa; Christoph Lange; Rafael Laniado-Laborín; Payam Nahid; Denise Rodrigues; Rupak Singla; Zarir F Udwadia; Dick Menzies Journal: Lancet Respir Med Date: 2020-03-17 Impact factor: 30.700
Authors: I Lucenko; V Riekstina; J Perevoscikovs; D Mozgis; M Khogali; J Gadoev; P de Colombani; A M V Kumar Journal: Public Health Action Date: 2014-10-21
Authors: L Kuksa; V Riekstina; V Leimane; I Ozere; G Skenders; R Van den Bergh; K Kremer; C D Acosta; A D Harries Journal: Public Health Action Date: 2014-10-21
Authors: Ann C Miller; A Katrina Nelson; Viktoria Livchits; Shelly F Greenfield; Galina Yanova; Sergei Yanov; Hilary S Connery; Sidney Atwood; Charmaine S Lastimoso; Sonya S Shin Journal: PLoS One Date: 2016-02-12 Impact factor: 3.240
Authors: Joel Philip Samuels; Aashna Sood; Jonathon R Campbell; Faiz Ahmad Khan; James Cameron Johnston Journal: Sci Rep Date: 2018-03-21 Impact factor: 4.379